Experimental drug targets brain inflammation in lewy body dementia
NCT ID NCT06815965
Summary
This study is testing whether a drug called neflamapimod is safe and well-tolerated in people with dementia with Lewy bodies. Researchers will give 25 participants the drug twice daily for 24 weeks and monitor for side effects while also checking if it might help with thinking skills and mobility. The main goal is to understand how the drug behaves in the body and whether it shows any early signs of helping control this progressive brain disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES (DLB) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Lariboisière - APHP; Centre de Neurologie Cognitive
Paris, 75010, France
-
Strasbourg University Hospital (Les Hopitaux Universitaires de Strasbourg)
Strasbourg, 67000, France
Conditions
Explore the condition pages connected to this study.